Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Emerging Strategies for Early Detection and Prevention of Atherosclerotic Cardiovascular...
share announcement

Emerging Strategies for Early Detection and Prevention of Atherosclerotic Cardiovascular Disease

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 1035

Special Issue Editors

Prof. Dr. Patrick W. Serruys

grade E-Mail Website
Guest Editor
Corrib Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland
Interests: interventional cardiology; cardiovascular imaging; coronary artery disease; valvular heart disease; clinical trial; innovation in medicne; pharmacotherapy
Dr. Tsung-Ying Tsai

E-Mail Website
Guest Editor
Corrib Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland
Interests: interventional cardiology; cardiovascular imaging; coronary artery disease; valvular heart disease; clinical trial
Dr. Pruthvi C Revaiah

E-Mail Website
Guest Editor
CORRIB Research Centre for Advanced Imaging and Core Laboratory, University of Galway, Galway, Ireland
Interests: general cardiology; interventional cardiology; coronary artery disease; valvular heart disease; atherosclerosis; cardiovascular imaging; coronary physiology

Special Issue Information

Dear Colleagues,

Atherosclerotic cardiovascular disease (ASCVD) continues to be the leading cause of mortality worldwide. ASCVD is a chronic inflammatory systemic disease that develops subclinically early in life but is often diagnosed at an advanced stage in the elderly, causing serious or even fatal events. Therefore, early detection and treatment of ASCVD, before symptoms develop, is of paramount importance.

Over the past ten years, we have witnessed tremendous advancements in non-invasive imaging modalities. Tools such as computed tomography (CT), carotid or other peripheral arteries ultrasound, magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) have revolutionized the diagnosis of asymptomatic ASCVD. Furthermore, biomarker technology has progressed beyond traditional lipid profiling and has entered the realms of "omics" and genetics.

These emerging technologies, bolstered by deep learning algorithms, promise to assist healthcare professionals in identifying high-risk individuals who may otherwise slip through the net of traditional risk stratification. For early treatment, our therapeutic arsenal is continually expanding. Current treatments include statins, ezetimibe, icosapent ethyl, and PCSK9 inhibitors that halt ASCVD progression via lipid-lowering mechanisms. Additionally, anti-inflammatory therapies such as Canakinumab and colchicine, as well as prospective gene therapies, are emerging.

In this Special Issue, we cordially invite you to submit your research on the following topics:

  1. Non-invasive imaging technologies for the early detection of atherosclerosis;
  2. Novel biomarker phenotyping for the identification of high-risk individuals;
  3. Innovative treatment approaches for asymptomatic ASCVD.

Your contributions will propel current clinical care into a new era of early detection and treatment.

Prof. Dr. Patrick W. Serruys
Dr. Tsung-Ying Tsai
Dr. Pruthvi C Revaiah
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • subclinical atherosclerosis
  • atherosclerotic cardiovascular disease (ASCVD)
  • early detection
  • non-invasive imaging
  • biomarkers
  • lipid-lowering therapy
  • anti-inflammation therapy
  • gene therapy
  • risk stratification

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 794 KiB  
Article
Estimating the Prevalence and Characteristics of Patients Potentially Eligible for Lipoprotein(a)-Lowering Therapies in a Real-World Setting
by Arrigo F. G. Cicero, Federica Fogacci, Marina Giovannini, Elisa Grandi, Sergio D’Addato and Claudio Borghi
Biomedicines 2023, 11(12), 3289; https://doi.org/10.3390/biomedicines11123289 - 12 Dec 2023
Cited by 1 | Viewed by 832
Abstract
High lipoprotein(a) (Lp(a)) plasma levels are significantly associated with an increased risk of developing atherosclerotic cardiovascular diseases (ASCVD). The aim of this analysis was to estimate the prevalence and characteristics of patients potentially eligible for Lp(a)-lowering therapies in a real-world setting (i.e., patients [...] Read more.
High lipoprotein(a) (Lp(a)) plasma levels are significantly associated with an increased risk of developing atherosclerotic cardiovascular diseases (ASCVD). The aim of this analysis was to estimate the prevalence and characteristics of patients potentially eligible for Lp(a)-lowering therapies in a real-world setting (i.e., patients with ASCVD and Lp(a) levels > 70 mg/dL). For this reason, we pooled data from a large cohort of Italian outpatients (N = 5961; men: 2879, women: 3982) with dyslipidemia. A binary logistic regression analysis was used to determine the significant predictors of ASCVD in the cohort, which were age (Odds Ratio (OR): 1.158, 95% Confidence Interval (CI): 1.114 to 1.203, p < 0.001), low-density lipoprotein cholesterol at entry (OR: 1.989, 95% CI: 1.080 to 1.198, p = 0.020) and Lp(a) (OR: 1.090, 95% CI: 1.074 to 1.107, p < 0.001). In our cohort, almost half of patients with ASCVD (44.7%) may be eligible to be treated with Lp(a)-lowering agents. Interestingly, patients who do not meet the treatment criteria despite high Lp(a) (50–70 mg/dL), respectively, account for 4.7% and 7.3% of those in primary and secondary ASCVD prevention. In conclusion, in our large cohort of outpatients with dyslipidemia, the prevalence of individuals with ASCVD and very high Lp(a) plasma levels is quite high, even with a conservative estimation. Full article
(This article belongs to the Special Issue Emerging Strategies for Early Detection and Prevention of Atherosclerotic Cardiovascular Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop